123 related articles for article (PubMed ID: 8286212)
21. Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry.
Kwock L; Gill M; McMurry HL; Beckman W; Raleigh JA; Joseph AP
Radiat Res; 1992 Jan; 129(1):71-8. PubMed ID: 1728059
[TBL] [Abstract][Full Text] [Related]
22. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.
Olive PL; Durand RE; Raleigh JA; Luo C; Aquino-Parsons C
Br J Cancer; 2000 Dec; 83(11):1525-31. PubMed ID: 11076663
[TBL] [Abstract][Full Text] [Related]
23. Hypoxic cell turnover in different solid tumor lines.
Ljungkvist AS; Bussink J; Kaanders JH; Rijken PF; Begg AC; Raleigh JA; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1157-68. PubMed ID: 15913908
[TBL] [Abstract][Full Text] [Related]
24. [Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
Shimizu Y
Yakugaku Zasshi; 2018; 138(11):1345-1352. PubMed ID: 30381642
[TBL] [Abstract][Full Text] [Related]
25. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
26. Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts.
Scigliano S; Pinel S; Poussier S; Fouyssac F; Plenat F; Karcher G; Chastagner P
Int J Oncol; 2008 Jan; 32(1):69-77. PubMed ID: 18097544
[TBL] [Abstract][Full Text] [Related]
27. Potential of nitroimidazoles as markers of hypoxia in heart.
Rumsey WL; Patel B; Kuczynski B; Narra RK; Chan YW; Linder KE; Cyr J; Raju N; Ramalingam K; Nunn AD
Adv Exp Med Biol; 1994; 345():263-70. PubMed ID: 8079717
[No Abstract] [Full Text] [Related]
28. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
Seddon BM; Maxwell RJ; Honess DJ; Grimshaw R; Raynaud F; Tozer GM; Workman P
Clin Cancer Res; 2002 Jul; 8(7):2323-35. PubMed ID: 12114437
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.
Webster L; Hodgkiss RJ; Wilson GD
Br J Cancer; 1998; 77(2):227-34. PubMed ID: 9460993
[TBL] [Abstract][Full Text] [Related]
30. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.
Arteel GE; Thurman RG; Yates JM; Raleigh JA
Br J Cancer; 1995 Oct; 72(4):889-95. PubMed ID: 7547236
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers.
Li Z; Chu T; Liu X; Wang X
Nucl Med Biol; 2005 Apr; 32(3):225-31. PubMed ID: 15820757
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of extracellular cyclic AMP-dependent protein kinase as a biomarker of cancer in dogs.
Bhang DH; Choi US; Kim BG; Lee SN; Lee S; Roh HS; Chung WJ; Jeon KO; Song WJ; Youn HY; Baek KH
Vet Comp Oncol; 2017 Dec; 15(4):1585-1589. PubMed ID: 28185388
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
[TBL] [Abstract][Full Text] [Related]
34. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole.
Garrecht BM; Chapman JD
Br J Radiol; 1983 Oct; 56(670):745-53. PubMed ID: 6616139
[TBL] [Abstract][Full Text] [Related]
35. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
He F; Deng X; Wen B; Liu Y; Sun X; Xing L; Minami A; Huang Y; Chen Q; Zanzonico PB; Ling CC; Li GC
Cancer Res; 2008 Oct; 68(20):8597-606. PubMed ID: 18922936
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, in vitro and in vivo characterization of two novel 68Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia.
Fernández S; Dematteis S; Giglio J; Cerecetto H; Rey A
Nucl Med Biol; 2013 Feb; 40(2):273-9. PubMed ID: 23218939
[TBL] [Abstract][Full Text] [Related]
38. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
[TBL] [Abstract][Full Text] [Related]
39. Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines.
Schilling D; Bayer C; Geurts-Moespot A; Sweep FC; Pruschy M; Mengele K; Sprague LD; Molls M
BMC Cancer; 2007 Jul; 7():143. PubMed ID: 17663760
[TBL] [Abstract][Full Text] [Related]
40. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix.
Jankovic B; Aquino-Parsons C; Raleigh JA; Stanbridge EJ; Durand RE; Banath JP; MacPhail SH; Olive PL
Cytometry B Clin Cytom; 2006 Mar; 70(2):45-55. PubMed ID: 16456867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
